Abstract. Since 1998, there has been a marked increase in incidence of pure red cell aplasia secondary to development of anti-
their formulation or route of administration. Eprex lacking human serum albumin (HSA) and administered subcutaneously was associated with the greatest risk of Ab ϩ PRCA. HSA-containing Eprex administered subcutaneously was associated with a lower risk than HSA-free Eprex administered subcutaneously, but this risk exceeded that of intravenous Epogen and intravenous HSA-free Eprex. NeoRecormon administered subcutaneously was associated with less risk than subcutaneous HSA-free Eprex but more risk than intravenous Epogen. HSA-free Eprex should not be administered subcutaneously to patients with CKD due to increased risk of Ab ϩ PRCA. Although the subcutaneous administration of HSA-containing Eprex is riskier than intravenous Epogen and intravenous HSA-free Eprex, and the use of subcutaneous NeoRecormon is riskier than intravenous Epogen, there is currently no evidence that other products are safer.
Pure red cell aplasia (PRCA) is a rare and serious hematologic disorder characterized by loss of erythroid progenitors from bone marrow, severe reticulocytopenia, and rapid onset of transfusiondependent anemia. Secondary forms of PRCA are associated with viral infections, thymomas, lymphoproliferative disorders, or autoimmune disorders such as lupus (1, 2) . Rarely, PRCA has been found to result from production of neutralizing autoantibodies against erythropoietin, a glycosylated polypeptide required for the terminal maturation of erythroid progenitors (3) (4) (5) .
The recombinant erythropoietin product epoetin was introduced into the management of anemia in patients with chronic kidney disease (CKD) in the late 1980s. Occasional case reports described patients with CKD who developed anti-erythropoietin antibody-positive PRCA (Ab ϩ PRCA) while on epoetin (6 -9 ). An apparent increase in incidence of Ab ϩ PRCA was recently noted in patients who have CKD and were given epoetin subcutaneously (10) . Postmarketing surveillance data collected by industry and regulators confirmed that a marked increase in incidence of PRCA occurred beginning in 1998 in CKD patients who were taking epoetin (11, 12) . Anti-erythropoietin antibodies were directed against the peptide rather than the carbohydrate moiety of the molecule and were shown to neutralize epoetin in biologic assays (10, 13) . Most cases of Ab ϩ PRCA have occurred in patients who receive Eprex (epoetin alfa; Ortho Biotech/Janssen-Ortho Inc., Toronto, Ontario, Canada) (11, 14) .
Several hypotheses have been proposed to explain the increased incidence of Ab ϩ PRCA. Most patients who developed Ab ϩ PRCA received epoetin subcutaneously (14, 15) , a route of administration that carries greater theoretical potential to stimulate antibody production than intravenous use (16) . The temporal relationship between the increased incidence of Ab ϩ PRCA and removal of human serum albumin (HSA) from most formulations of Eprex suggested that this change may be responsible for increased anti-erythropoietin antibody formation (14) . Distribution of Eprex formulations stabilized with HSA was discontinued in most countries between 1998 and 2001 in response to concerns from European regulatory agencies regarding the theoretical risk of transmission of infectious agents in human products (14, 17) (Ortho Biotech, communication to Canadian PRCA Focus Group). The formulation of other erythropoietin products remained unchanged. However, several manufacturers confirm the stability of the protein in HSA-free formulations of their erythropoietin products (Amgen, Ortho Biotech, and Roche, communications to Canadian PRCA Focus Group). Storage of erythropoietin products at temperatures above 8°C may promote aggregation or unfolding, resulting in an immune response (16) . Inadequate handling may result from the practice of increased self-administration. Silicone oil on plungers in prefilled syringes has been suggested to destabilize erythropoietin products (14) . Finally, the HSA-free formulation of Eprex, but not NeoRecormon, was recently reported to contain micelle-associated epoetin, which may be a risk factor for the development of antibodies against epoetin (22) .
Manufacturers have found no evidence indicating a loss of integrity of the recombinant erythropoietin molecule. Changes introduced into the manufacturing process of Eprex between 1996 and 1999 were analyzed by the manufacturer, which concluded that "the bulk product is within our stringent specifications" (17) . Inspections conducted by the U.S. Food and Drug Administration in October 2001 and by the Agence Française de Sécurité Sanitaire des Produits de Santé in June 2002 examined the manufacturing process and identified "minor issues that were addressed" by the manufacturer (18) .
Almost all cases of Ab ϩ PRCA after use of erythropoietin products have been in patients with CKD, despite their use for other indications, including the treatment of anemia in cancer patients (11, 14) . The reason for this preponderance is unclear. It may relate to prolonged exposure (14) , effects of uremia on erythropoiesis (19) , and absence of concomitant severe immune suppression.
In response to the increased incidence of Ab ϩ PRCA in patients with CKD, one manufacturer of erythropoietin products (Ortho Biotech) established a multidisciplinary Canadian PRCA Focus Group, composed of experts in hematology, hematopathology, nephrology, epidemiology, and erythropoietin receptor biology. The mandate of this group was to review current practice of erythropoietin therapy in CKD, assess diagnostic criteria for Ab ϩ PRCA, develop monitoring strategies for patients who are taking erythropoietin products, and make recommendations to minimize the risk of Ab ϩ PRCA. In this report, postmarketing data provided by manufacturers were analyzed for associations between the risk of developing Ab ϩ PRCA and erythropoietin products, formulation, and route of administration. Recommendations are made to minimize the risk of developing Ab ϩ PRCA among CKD patients who are taking recombinant erythropoietin.
Materials and Methods

Sources of Data
Manufacturers of recombinant erythropoietin products were asked to provide postmarketing surveillance data showing incidence of Ab ϩ PRCA and estimated patient exposure data by product, formulation, and route of administration for patients with CKD from January 1998 to March 2003. This information was provided by Ortho Biotech (manufacturer of Eprex) and Amgen (Thousand Oaks, CA; manufacturer of Epogen, Procrit, and Aranesp; communications to Canadian PRCA Focus Group). Roche (Basel, Switzerland; manufacturer of NeoRecormon) contributed data for the period from January 1998 to June 2003 (communication to Canadian PRCA Focus Group) (12) . All cases of suspected PRCA in which anti-erythropoietin antibodies were detected, regardless of the antibody assay method used, were considered Ab ϩ PRCA. Suspected PRCA included all cases in which information supported a suspicion of PRCA when the safety report was filed, typically because the patient's hemoglobin level dropped unexpectedly, and in the absence of other causes while on recombinant erythropoietin therapy to which the patient had previously responded. All cases of suspected PRCA that were anti-erythropoietin antibody negative were excluded from our analysis. Patient exposure estimates were based on sales, estimated number of patients treated, and estimated mean dose per patient. The data were validated by the manufacturers at completion of the analysis and conformed to information submitted to regulatory bodies. Analysis, interpretation, and recommendations were not subject to manufacturer approval.
Statistical Analyses
The incidence of Ab ϩ PRCA among different products, formulations, and routes of administration was evaluated. PRCA cases were included only for patients who were exposed to a single erythropoietin product, with known route of administration and date of loss of efficacy. Because Ab ϩ PRCA events are rare and zero events are possible, it was assumed that the observations were generated by a Poisson distribution. A maximum likelihood estimate and an exact confidence interval (CI) for the Poisson rate parameter were calculated from the observed number of Ab ϩ PRCA events and patient exposure for each product, formulation, and route of administration. A test of whether the Poisson rate was the same for several independent processes (test for homogeneity) was conducted. The software StatXact-5 (5.0.3; Cytel Software Corporation, Cambridge, MA) was used to perform the calculations.
Role of the Funding Source
The study sponsor (Ortho Biotech) provided data on incidence of Ab ϩ PRCA in patients who received Eprex but had no role in the collection of other data. The study sponsor had no role in study design, the analysis or interpretation of data, the writing of the report, or the decision to submit the paper for publication.
Results
On the basis of observed incidence of Ab ϩ PRCA and exposure to the various erythropoietin products (Table 1) , a maximum likelihood estimate of the incidence that would be observed at infinite exposure and an exact CI for the Poisson rate parameter were calculated for each product. The 95% CI of the likelihood estimates of incidence were compared for each erythropoietin product, by formulation and route of administration (Table 2 ). Because there is no meaningful statistical method that allows comparison of null incidences, estimated incidences of Ab ϩ PRCA could not be compared between erythropoietin products for which no cases were observed for either product. Significant differences in likelihood estimates of Ab ϩ PRCA incidence were observed between several products.
Eprex
Eprex (epoetin alfa; Ortho Biotech) is distributed outside the United States. HSA-containing formulations of Eprex were progressively removed from most countries, except Canada and Turkey, starting in 1998, but HSA-containing products were available in some countries as late as 2001.
Most cases of Ab ϩ PRCA have been associated with Eprex, with a global incidence of 13.8 cases per 100,000 patient-years when all formulations and routes of administration are combined ( Table 1 ). The risk of developing Ab ϩ PRCA with Eprex is solely associated with subcutaneous administration, resulting in an observed incidence of 20.9 cases per 100,000 patientyears when both formulations of the product are combined. In contrast, there were no cases of Ab ϩ PRCA in patients who received Eprex (HSA-free or HSA-containing) intravenously in Ͼ395,000 patient-years. The estimated risk of Ab ϩ PRCA associated with intravenous administration of either formulation does not exceed the risk associated with any other erythropoietin product and is lower than the risk associated with subcutaneous administration of Eprex (Table 2 ). In contrast, the risk of developing Ab ϩ PRCA with subcutaneous administration of Eprex is strongly influenced by product formulation. Incidences of 26.9 and 2.2 cases per 100,000 patient-years were observed with HSA-free and HSA-containing formulations, respectively (Table 1 ). Comparing likelihood estimates of incidences (Table 2 ), the risk of Ab ϩ PRCA associated with HSA-free Eprex administered subcutaneously is greater than that associated with any other erythropoietin product except HSA-containing Aranesp administered intravenously. The lack of difference in the risk associated with subcutaneous HSAfree Eprex and intravenous HSA-containing Aranesp may reflect limited exposure to the latter product. Subcutaneous use of HSA-containing Eprex carries a higher risk than intravenously administered Epogen and HSA-free Eprex ( hood estimate of risk for this product is not affected by route of administration (P ϭ 1). The risk associated with intravenous administration of Epogen is not statistically distinguishable from other erythropoietin products, except for Eprex and NeoRecormon administered subcutaneously ( Table 2 ). The risk associated with subcutaneous administration of Epogen is statistically distinguishable only from HSA-free Eprex administered subcutaneously (Table 2) .
Procrit
Procrit (epoetin alfa; Ortho Biotech) is produced by Amgen as an HSA-containing formulation using the same facility and process as for Epogen. It is distributed by Ortho Biotech solely in the United States. Data were obtained for predialysis patients who all received this medication subcutaneously. The risk of Ab ϩ PRCA with subcutaneous Procrit is statistically distinguishable only from HSA-free Eprex administered subcutaneously (Table 2) .
NeoRecormon
NeoRecormon (epoetin beta; Roche) is distributed in Europe as an HSA-free formulation. Other than differences in the vehicles, oligosaccharide content, and degree of oligosaccharide sialylation (20, 21, 22) , the mixture of molecules in epoetin beta preparations is similar to that in epoetin alfa preparations. There have been eight reports of Ab ϩ PRCA in CKD patients who received NeoRecormon subcutaneously, for an incidence of 1.6 cases per 100,000 patient-years (12) . The risk of Ab ϩ PRCA with intravenous administration of NeoRecormon is statistically distinguishable only from HSA-free Eprex administered subcutaneously ( Table 2 ). The risk associated with subcutaneous administration of NeoRecormon is less than that associated with subcutaneous HSA-free Eprex (P Ͻ 0.0001) but greater than that associated with intravenous Epogen (P ϭ 0.005), and not significantly different from that associated with other erythropoietin products and/or routes af administration (Table 2) .
Aranesp
Aranesp (darbepoetin alfa; Amgen) was licensed in the second half of 2001 for CKD patients in the United States, Europe, and Australia and in August 2002 in Canada. An HSA-containing formulation is available in the United States, and an HSA-free formulation is available elsewhere. Aranesp bears five amino acid substitutions and two additional N-linked oligosaccharides relative to epoetin alfa and epoetin beta, thus increasing its in vivo half-life and biologic activity (23) . As of March 31, 2003, the global exposure to Aranesp in CKD patients was estimated at 82,000 patient-years, including 55,000 patient-years for subcutaneous use (Table 1) . No cases of Ab ϩ PRCA have been observed so far with either formulation or route of administration. The risk associated with Aranesp is not significantly different from that associated with Epogen, Procrit, subcutaneous NeoRecormon, or HSA-containing subcutaneous Eprex ( Table 2 ). The risk of Ab ϩ PRCA associated with all formulations and routes of administration of Aranesp is lower than that with subcutaneous HSA-free Eprex (P Յ 0.01), except for intravenous HSA-containing Aranesp. For this product, the exposure is limited and there is no significant difference in the likelihood estimates of risk compared with that for subcutaneous HSA-free Eprex (P ϭ 0.4).
Discussion
Although its incidence has increased sharply since 1998 among CKD patients who take recombinant erythropoietin products, Ab ϩ PRCA remains a relatively rare complication. Including cases with exposure to multiple erythropoietin products,~200 confirmed cases (Table 1) (17) were reported in Ͼ3.5 million patient-years between January 1998 and March 2003, with peak incidence occurring in 2001 (17) . Observed and maximum estimated incidences varied significantly between products. The risk of developing Ab ϩ PRCA is strongly associated with the subcutaneous administration of Eprex (Tables 1 and 2). The risk is greatest among those who receive HSA-free Eprex (26.9 cases per 100,000 patient-years) and is significantly less for the HSA-containing formulation (2.2 cases per 100,000 patient-years). However, subcutaneously administered HSA-containing Eprex has a greater risk of Ab ϩ PRCA than treatment with intravenously administered Epogen or HSA-free Eprex. In contrast, the risk associated with Eprex administered intravenously does not exceed that of other erythropoietin products. Subcutaneous NeoRecormon is associated with a lower risk of Ab ϩ PRCA than subcutaneous HSA-free Eprex but a greater risk than that associated with intravenous Epogen. Because no comparisons can be made between products with a null incidence of Ab ϩ PRCA, the relative risks of certain pairs of erythropoietin products could not be compared.
The relatively high incidence of Ab ϩ PRCA in patients who receive erythropoietin products subcutaneously has been noted before (14, 15, 24) . "Recall" skin reactions were observed in one patient at sites of previous subcutaneous injections after intravenous epoetin administration (25) . Our analysis supports speculations that removal of HSA from erythropoietin products may have contributed to the increased incidence of Ab ϩ PRCA (14) with subcutaneous Eprex. However, removal of HSA does not seem to be the only factor, because HSA-containing Eprex administered subcutaneously carries a greater risk of Ab ϩ PRCA than HSA-free Eprex administered intravenously (Table  2) , and subcutaneous HSA-free Aranesp and NeoRecormon are associated with a lower risk than subcutaneous HSA-free Eprex.
These results should be considered in light of the limitations of pharmacovigilance data. Risk analysis for Ab ϩ PRCA was performed on data generated by self-reporting and marketing rather than through a prospective study. However, because of the rarity of the event and the average delay in its development, a clinical trial assessing incidence of Ab ϩ PRCA in patients who are treated with the various erythropoietin products would be impractical. An estimation of the relative risks of erythropoietin products was needed sooner than could be provided by such a trial. Because development of Ab ϩ PRCA is rare, there was concern that small changes in the pharmacovigilance data might alter the statistical significance of comparisons between products. To test the robustness of incidence comparisons with P values nearest 0.05 (i.e., the seven comparisons with P values ranging from 0.004 to 0.09; see Table 2 ), number of Ab ϩ PRCA cases or patient exposure was varied individually for each product in each comparison. Only two comparisons were considered sensitive to variation of the data: Either subcutaneously administered NeoRecormon or subcutaneously administered HSA-containing Eprex versus intravenously administered HSA-free Eprex. Relatively small changes made the first comparison significant and the second comparison nonsignificant. Because these subcutaneously administered products were already noted to carry significantly more risk than Epogen administered intravenously, the sensitivity of these comparisons does not alter our main recommendations below.
Other limitations should be recognized. The analysis focused on the patient group with highest risk during a time interval when awareness changed over time. Consideration of only antibody-positive cases may underestimate the true incidence of PRCA associated with erythropoietin products but related to other mechanisms such as cell-mediated immunity. Estimates of patient exposure on the basis of amount of product sold since 1998 may be distorted by persisting circulation of products sold before 1998. The comparison between products was limited in part by significant differences in exposure. Because uncertainty in risk decreases as exposure increases, upper risk limits for developing Ab ϩ PRCA are much closer to observed incidences for products with higher exposure. For products with low exposure, the 95% CI estimating the risk of incidence is necessarily wide; thus, the upper limit of the CI is likely more distant from the actual risk. Given that the median individual exposure to erythropoietin products is~9 mo in patients who develop Ab ϩ PRCA (14) , risk may be underestimated for products with shorter average duration of exposure. Unfortunately, information about average duration of exposure to erythropoietin products is not available. Despite the relatively low absolute incidence of Ab ϩ PRCA for all recombinant erythropoietin products currently marketed, the seriousness of this complication justifies every reasonable effort to minimize its occurrence. The cumulative risk of Ab ϩ PRCA during long-term exposure of CKD patients to some erythropoietin products is comparable to that of other serious drug-related hematotoxicities for which risk minimization is of recognized importance. One example is the irreversible aplastic anemia that develops in one in 25,000 to 40,000 patients who receive chloramphenicol (26) . The first principle in minimization of risk is to weigh carefully the potential harm and benefit of the use of erythropoietin products.
The following conclusions and recommendations can be formulated at this time for CKD patients. Although no conclusive clinical evidence links the increased occurrence of Ab ϩ PRCA to storage and handling, recombinant erythropoietin products should be maintained under recommended conditions that are known to preserve their integrity. There is no significant difference in the estimated risk of developing Ab ϩ PRCA among any of the intravenously administered products that are currently available. HSA-free Eprex administered subcutaneously is associated with the greatest risk and should not be given to CKD patients when other appropriate alternatives are available. HSA-containing Eprex administered subcutaneously is associated with a lower risk. This risk exceeds that of intravenous Epogen and intravenous HSA-free Eprex, but is indistinguishable from that of other products (Table 2) . Subcutaneously administered NeoRecormon carries less risk than subcutaneously administered HSA-free Eprex. The risk associated with subcutaneous NeoRecormon is greater than that of intravenous Epogen, but there is no statistically significant difference between the risk of subcutaneous NeoRecormon and other erythropoietin products and routes of administration. Given the morbidity associated with venous accesses, the levels of risk associated with subcutaneous administration of HSA-containing Eprex or NeoRecormon do not justify intravenous administration in patients without established vascular access. Route of administration does not detectably influence the risk of Ab ϩ PRCA associated with erythropoietin products other than Eprex. It should be noted that these recommendations concerning Eprex are consistent with current prescribing information from the manufacturer in Europe (27) and Canada (28) .
Postmarketing identification of adverse drug effects is a continuing challenge. In many developed countries, programs to which health care professionals may voluntarily report adverse drug effects currently exist. However, there is little systematic independent analysis of accumulated data. To improve this system, regulatory bodies should establish independent, multidisciplinary groups of experts who are qualified to evaluate potential adverse effects of each new product. Such groups should have legally mandated access to source data on patient exposure and incidence of adverse effects. The expert groups should report their findings to regulators as appropriate, and the information should be disseminated rapidly to the medical community. Establishment of a system for multidisciplinary, independent review of adverse events should enhance detection of associations between medical products and unanticipated adverse effects.
